The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

November is Diabetes Awareness Month; it’s a disease that affects millions of people across the United States – both with ...

One of the primary challenges in the regulatory affairs of the pharmaceutical industry is keeping pace with the ever-evolving regulatory landscape.

"Companies like Novartis, BMS, Sanofi, Amgen, Roche, Sandoz, Thermofisher, Bayer, and Zoetis have their centres here that are ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

Zucara Therapeutics Inc., a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, announced that ...

If Kennedy is confirmed, we may lower our US vaccine sales estimates, although we don’t think reductions would be ...

The context: Last week, shares in US vaccine manufacturers Pfizer and Moderna, as well as in European counterparts GSK and ...

New research published by the European Federation of Industries and Associations (EFPIA) provides in-depth analysis of the ...

Sanofi's Chief Digital Officer Emmanuel Frenehard had a thought that he just couldn't shake: how can Sanofi extend the ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for ...